Updated on: 15 August 2017

Roles in: Z_INACTIVE_Neuromuscular Group

1. In the past 36 months have you accepted the following from a commercial organisation with a financial interest in the broad topic area of the Group/Unit?

a) Support for attending meetings, including sabbaticals and study tours (this covers travel, accommodation and/or hospitality)?
No

b) Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events?
No

c) Fees for organising education?
No

d) Grants and contracts?
Yes - Alnylam Pharmaceuticals: APOLLO: a phase 3 multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Patisiran (ALN-TTR02) in transthyretin (TTR)-mediated polyneuropathy (familial amyloidotic polyneuropathy-FAP). Coinvestigator. 2015- ISIS Pharmaceuticals: A phase 3 open-label extension study to assess the long-term safety and efficacy of ISIS 420915 in patients with familial amyloid polyneuropathy (FAP). Coinvestigator. 2015-

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - Chair of Data and Safety Monitoring Committee. Effects of ODM-109 on Respiratory Function in patients with ALS. Orion Pharmaceuticals. (2015- 2017)

g) Royalty or licences payments?
No

2. In the past 36 months have you, your spouse/partner or an immediate family member been employed by or do you or they own a commercial organization with a financial interest in the broad topic area of the Group/Unit?
No

3. Do you own stocks or shares in a commercial organization with a financial interest in the broad topic area of the Group/Unit?
No

4. Do you hold any patents (planned, issued or pending) for products relevant to the broad topic area of the Group/Unit?
No

5. Do you have any other competing interests (financial or non-financial)?
No